SCYX4:30 PMSCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateTrial Start • Phase 1Trial initiation Tue, Jun 30, 2026, 4:30 PM EDTGscynexis.com
SCYX8:00 AMSCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Trial Start • Phase 1Trial initiation Tue, Jun 30, 2026, 8:00 AM EDTGscynexis.com